DK0690850T3 - 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister - Google Patents
2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonisterInfo
- Publication number
- DK0690850T3 DK0690850T3 DK94911608.1T DK94911608T DK0690850T3 DK 0690850 T3 DK0690850 T3 DK 0690850T3 DK 94911608 T DK94911608 T DK 94911608T DK 0690850 T3 DK0690850 T3 DK 0690850T3
- Authority
- DK
- Denmark
- Prior art keywords
- pct
- formula
- sec
- date
- substituted morpholine
- Prior art date
Links
- -1 2-Substituted morpholine Chemical class 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000004886 thiomorpholines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010038678 Respiratory depression Diseases 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000003931 cognitive performance Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
- C07F9/65335—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3858493A | 1993-03-26 | 1993-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0690850T3 true DK0690850T3 (da) | 1998-02-09 |
Family
ID=21900746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94911608.1T DK0690850T3 (da) | 1993-03-26 | 1994-03-23 | 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5929236A (da) |
| EP (1) | EP0690850B1 (da) |
| JP (1) | JP2778832B2 (da) |
| AT (1) | ATE160143T1 (da) |
| AU (1) | AU6408894A (da) |
| CA (1) | CA2158952C (da) |
| DE (1) | DE69406779T2 (da) |
| DK (1) | DK0690850T3 (da) |
| ES (1) | ES2109683T3 (da) |
| GR (1) | GR3025950T3 (da) |
| IL (1) | IL109111A (da) |
| TW (1) | TW280817B (da) |
| WO (1) | WO1994022843A1 (da) |
| ZA (1) | ZA942090B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ66498A3 (cs) * | 1995-09-07 | 1998-07-15 | Novartis Ag | Substituované fosfinové kyseliny, způsoby jejich přípravy, farmaceutický prostředek, který je obsahuje, a jejich použití |
| WO1998028313A1 (en) * | 1996-12-24 | 1998-07-02 | Novartis Ag | (thio)morpholine-substituted carboxylic and phosphinic acids |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889857A (en) * | 1987-10-12 | 1989-12-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Quinolonecarboxylic acid compounds and pharmaceutical use thereof |
| NZ233503A (en) * | 1989-05-15 | 1991-06-25 | Janssen Pharmaceutica Nv | Substituted (thio)morpholinyl and piperazinyl alkylphenol ethers |
| JPH04270272A (ja) * | 1991-02-25 | 1992-09-25 | Yoshitomi Pharmaceut Ind Ltd | アミノアルキルモルホリン誘導体の製造法 |
-
1994
- 1994-03-23 US US08/525,795 patent/US5929236A/en not_active Expired - Fee Related
- 1994-03-23 DK DK94911608.1T patent/DK0690850T3/da active
- 1994-03-23 ES ES94911608T patent/ES2109683T3/es not_active Expired - Lifetime
- 1994-03-23 EP EP94911608A patent/EP0690850B1/en not_active Expired - Lifetime
- 1994-03-23 CA CA002158952A patent/CA2158952C/en not_active Expired - Fee Related
- 1994-03-23 JP JP6522103A patent/JP2778832B2/ja not_active Expired - Fee Related
- 1994-03-23 AT AT94911608T patent/ATE160143T1/de not_active IP Right Cessation
- 1994-03-23 DE DE69406779T patent/DE69406779T2/de not_active Expired - Lifetime
- 1994-03-23 WO PCT/US1994/002803 patent/WO1994022843A1/en active IP Right Grant
- 1994-03-23 AU AU64088/94A patent/AU6408894A/en not_active Abandoned
- 1994-03-24 IL IL10911194A patent/IL109111A/en not_active IP Right Cessation
- 1994-03-24 ZA ZA942090A patent/ZA942090B/xx unknown
- 1994-03-24 TW TW083102586A patent/TW280817B/zh active
-
1998
- 1998-01-20 GR GR980400120T patent/GR3025950T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2158952C (en) | 1999-05-18 |
| IL109111A (en) | 1999-07-14 |
| WO1994022843A1 (en) | 1994-10-13 |
| TW280817B (da) | 1996-07-11 |
| JP2778832B2 (ja) | 1998-07-23 |
| US5929236A (en) | 1999-07-27 |
| ZA942090B (en) | 1994-09-26 |
| ES2109683T3 (es) | 1998-01-16 |
| ATE160143T1 (de) | 1997-11-15 |
| DE69406779D1 (en) | 1997-12-18 |
| CA2158952A1 (en) | 1994-10-13 |
| JPH08503229A (ja) | 1996-04-09 |
| EP0690850B1 (en) | 1997-11-12 |
| GR3025950T3 (en) | 1998-04-30 |
| IL109111A0 (en) | 1994-06-24 |
| DE69406779T2 (de) | 1998-03-12 |
| AU6408894A (en) | 1994-10-24 |
| EP0690850A1 (en) | 1996-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY137348A (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| DK0527687T3 (da) | Hidtil ukendte arylethylaminderivater, fremgansmåder til fremstilling heraf og farmaceutiske midler, som indeholder dem | |
| MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
| KR880012218A (ko) | 캘폰 유도체를 사용한 다발성 경화증의 치료방법 | |
| DK0690850T3 (da) | 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister | |
| ES2179996T3 (es) | Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos. | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
| TR199701497T1 (xx) | Beyin �demini �nleyen terkip. | |
| BR0008778A (pt) | Análogos de prostaglandinas seletivos para fpc16 insaturados | |
| ES2111352T3 (es) | Uso de diester fosfato para el tratamiento de enfermedades retinianas. | |
| MX9707596A (es) | Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo. | |
| DE69421694D1 (en) | Interleukin-1 inhibitor | |
| SE9702716D0 (sv) | Substituted phenylazacycloalkanes in the treatment of cognitive disorders | |
| BR9809313A (pt) | Compostos, promedicamento, medicamento, processo para a sua preparação e utilização dos mesmos | |
| ES2094638T3 (es) | N-acilpirrolidinas y medicamentos para el tratamiento o la prevencion de los desordenes relacionados con la colecistoquinina y la gastrina. | |
| ES2138017T3 (es) | Uso de n-(piridinil)-1h-indol-1-aminas para la preparacion de un medicamento para el tratamiento de trastornos obsesivo-compulsivos. | |
| ES552193A0 (es) | Un procedimiento para la preparacion de nuevos peptidos. | |
| UA66751C2 (en) | Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment | |
| ES2065855B1 (es) | Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos. | |
| SE9802546D0 (sv) | Medicinal product and method for treatment and prevention of dyskinesia | |
| BR9306870A (pt) | Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol | |
| SE9401965D0 (sv) | New compounds | |
| MY124089A (en) | Use of cetirizine for preventing the onset of asthma |